

#### We are GL RAPHA

GL Rapha is a pharmaceutical company anchored in love, built on trust, and cultivated with action. GL has devoted itself to the health and quality of life for all people.


GL is committed to provide effective and affordable medicines to meet the health needs of the global community. Our subsidiary Hankook Korus Pharm produce high quality generic chemical and biological products at three manufacturing facilities. We are continually investing in the development of beneficial products and cost effective production methods. We are currently expanding our Bio-product production facility to meet the growing demand.

GL continues to develop innovative ways to reach the places of need. Beyond trade, we are striving to achieve mutual growth with our international partners through global-localization of our technology via synergistic collaborations and business ventures worldwide. We work with local companies and governments to facilitate localization of our manufacturing technology in our partners homeland making medicines more accessible to a wider global community.


Join us in this quest of health and quality of life for all people.




### History



#### Organization



### Manufacturing Sites



#### **Chuncheon** (Bio-Plant)

Location : 11, Geodudanji 1-gil, Dongnae-myeon, Chuncheon-si, Gangwon-do, Korea

**Products: Biopharmaceuticals** (EPO, hGH, PEG-IFN alpha-2b, G-CSF)

- GMP approved for Bio Product
- Renovation to be Completed in 2018



#### **Eumseong** (Injectable Plant)

**Products: Powder injectables** of Cephalosporin antibiotic

- Acquired from Sanofi-Aventis Korea in 2009
- PIC/s GMP approved for injectable
- Annual production capacity up to 10 million vials/year




#### **Jecheon** (OSD Plant)

#### Products: About 120 generic grugs

- PIC/s GMP approved for Oral Dosage Form
- R&D center for developing chemical drugs / Separated manufacturing site for Cepha. antibiotics
- Annual producton capacity up to 700 million tablets/year, 20 million antibiotics/year, 10 million capsules/year
- Expansion plan for Cephalosporin Injectable products is under designing process






### Bio Pharmaceuticals


#### ► HEALivery® Platform Technology







#### **▶** Pipeline



## Network



### ► Liaison Office

- O 67562, Morskaya 50a, Kryzhanirkayl, Obssa City Ukraine
- O50057, Manas st. 83-1, Almaty, Kazakhstan
- Unit12-No3, Noor Avenue, Africa Blvd, Tehran/Iran
  Kardal Co No1, Incekmal, Ankra, Turkey

- Lazar 2 canter, plot No. 2722, Fectron No. 6, Bloc C Clst Floor 1, Rawda, Bauchrieh, Lebanon
  10AV. 4- 07 zona15, Lode Contreras, Condomino Jardines de Dóna Victoria Case #24 Guatemala

## Memo

_
_
_
_
_



# Memo





